SG11202002192QA - Restoration of t cell activity via the cd39/cd73 axis - Google Patents
Restoration of t cell activity via the cd39/cd73 axisInfo
- Publication number
- SG11202002192QA SG11202002192QA SG11202002192QA SG11202002192QA SG11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA SG 11202002192Q A SG11202002192Q A SG 11202002192QA
- Authority
- SG
- Singapore
- Prior art keywords
- restoration
- axis
- cell activity
- activity via
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568812P | 2017-10-06 | 2017-10-06 | |
| US201862686143P | 2018-06-18 | 2018-06-18 | |
| PCT/EP2018/077217 WO2019068907A1 (en) | 2017-10-06 | 2018-10-05 | Restoration of t cell activity via the cd39/cd73 axis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002192QA true SG11202002192QA (en) | 2020-04-29 |
Family
ID=63799006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002192QA SG11202002192QA (en) | 2017-10-06 | 2018-10-05 | Restoration of t cell activity via the cd39/cd73 axis |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190218308A1 (en) |
| EP (1) | EP3692068B1 (en) |
| JP (1) | JP7274469B2 (en) |
| KR (1) | KR20200060471A (en) |
| CN (1) | CN111542539B (en) |
| AU (1) | AU2018346447A1 (en) |
| BR (1) | BR112020006809A2 (en) |
| CA (1) | CA3074588A1 (en) |
| IL (1) | IL273414A (en) |
| SG (1) | SG11202002192QA (en) |
| WO (1) | WO2019068907A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2238170T (en) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| GB2545676A (en) * | 2015-12-21 | 2017-06-28 | Dublin Inst Of Tech | Prediction of therapeutic response using vibrational spectroscopy |
| CN110382544B (en) | 2017-03-16 | 2023-12-22 | 先天制药公司 | Compositions and methods for treating cancer |
| US11345757B2 (en) | 2017-07-31 | 2022-05-31 | Trishula Therapeutics, Inc. | Anti-CD39 antibodies |
| KR20210023983A (en) | 2018-06-18 | 2021-03-04 | 이나뜨 파르마 | Compositions and methods for treating cancer |
| EP3999545A4 (en) * | 2019-08-21 | 2023-09-13 | Harbour Biomed (Shanghai) Co., Ltd | Anti-cd73 antibody and application thereof |
| WO2021037037A1 (en) * | 2019-08-27 | 2021-03-04 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel anti-cd39 antibodies |
| CN110407941B (en) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | High affinity antibodies to CD39 and uses thereof |
| CN114651013A (en) * | 2019-11-05 | 2022-06-21 | 北京加科思新药研发有限公司 | Binding molecules specific for CD39 and uses thereof |
| US20230348599A1 (en) * | 2019-12-19 | 2023-11-02 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| US20220133902A1 (en) * | 2020-11-04 | 2022-05-05 | Heidelberg Pharma Research Gmbh | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy |
| UY39638A (en) * | 2021-02-19 | 2022-08-31 | Janssen Biotech Inc | MATERIALS AND METHODS FOR TARGETING REGULATORY T CELLS TO ENHANCE IMMUNE SURVEILLANCE |
| TW202340243A (en) | 2022-03-03 | 2023-10-16 | 美商阿克思生物科學有限公司 | Anti-cd39 antibodies and use thereof |
| WO2023236968A1 (en) * | 2022-06-08 | 2023-12-14 | 上海华奥泰生物药业股份有限公司 | Cd39/cd73 bispecific antigen binding protein and use thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6387645B1 (en) * | 1998-07-16 | 2002-05-14 | Hyseq, Inc. | Methods and materials relating to novel CD39-like polypeptides |
| SI2439273T1 (en) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| CN101248089A (en) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | Human monoclonal antibodies to programmed death ligand 1(PD-L1) |
| WO2009014708A2 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| PT2238170T (en) | 2008-01-31 | 2017-02-21 | Inserm - Inst Nat De La Santé Et De La Rech Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| WO2009101611A1 (en) | 2008-02-11 | 2009-08-20 | Curetech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
| UA109108C2 (en) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Anti-pd-ll antibody and its use to enhance t-cell function |
| ES2646863T3 (en) | 2009-11-24 | 2017-12-18 | Medimmune Limited | B7-H1 specific binding agents |
| DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
| CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| WO2013117647A1 (en) * | 2012-02-07 | 2013-08-15 | Innate Pharma | Mica binding agents |
| FR3011240A1 (en) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | 5'-NUCLEOTIDASE INHIBITORS AND THERAPEUTIC USES THEREOF |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP6657182B2 (en) | 2014-04-25 | 2020-03-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Purine derivatives as CD73 inhibitors for cancer treatment |
| BR112017006464A2 (en) * | 2014-10-10 | 2018-01-30 | Innate Pharma | cd73 lock |
| DK3218406T3 (en) | 2014-11-10 | 2021-06-21 | Medimmune Ltd | BINDING MOLECULES SPECIFIC TO CD73 AND USES THEREOF |
| US10100129B2 (en) | 2014-11-21 | 2018-10-16 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| EP3259288A1 (en) | 2015-02-20 | 2017-12-27 | Innate Pharma | Cd73 blockade |
| WO2017064043A1 (en) * | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| CA3005986A1 (en) | 2015-11-23 | 2017-06-01 | Innate Pharma | Cd39 vascular isoform targeting agents |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| CA3007646A1 (en) | 2015-12-09 | 2017-06-15 | Bioatla, Llc | Humanized anti-cd73 antibodies |
| CN108697719B (en) | 2016-01-08 | 2024-03-19 | 艾库斯生物科学有限公司 | Modulators of extracellular 5' -nucleotidases and uses thereof |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | Inhibitors of cd73-mediated immunosuppression |
| CN110382544B (en) * | 2017-03-16 | 2023-12-22 | 先天制药公司 | Compositions and methods for treating cancer |
| WO2019096900A1 (en) * | 2017-11-15 | 2019-05-23 | Innate Pharma | Potentiating the effect of atp release |
| KR20220002959A (en) * | 2019-04-23 | 2022-01-07 | 이나뜨 파르마 에스.에이. | CD73 blocking antibody |
| KR20220061977A (en) * | 2019-08-12 | 2022-05-13 | 퓨리노미아 바이오테크, 아이엔씨. | Methods and compositions for promoting and enhancing T cell mediated immune response through ADCC targeting of CD39 expressing cells |
-
2018
- 2018-10-05 WO PCT/EP2018/077217 patent/WO2019068907A1/en unknown
- 2018-10-05 CA CA3074588A patent/CA3074588A1/en active Pending
- 2018-10-05 SG SG11202002192QA patent/SG11202002192QA/en unknown
- 2018-10-05 BR BR112020006809-8A patent/BR112020006809A2/en unknown
- 2018-10-05 EP EP18783458.5A patent/EP3692068B1/en active Active
- 2018-10-05 AU AU2018346447A patent/AU2018346447A1/en active Pending
- 2018-10-05 JP JP2020519404A patent/JP7274469B2/en active Active
- 2018-10-05 KR KR1020207012268A patent/KR20200060471A/en not_active Application Discontinuation
- 2018-10-05 CN CN201880064186.3A patent/CN111542539B/en active Active
-
2019
- 2019-03-29 US US16/370,726 patent/US20190218308A1/en not_active Abandoned
-
2020
- 2020-03-18 IL IL273414A patent/IL273414A/en unknown
-
2022
- 2022-07-28 US US17/876,164 patent/US20230099801A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3692068B1 (en) | 2022-12-07 |
| BR112020006809A2 (en) | 2020-10-06 |
| JP7274469B2 (en) | 2023-05-16 |
| US20230099801A1 (en) | 2023-03-30 |
| JP2020536109A (en) | 2020-12-10 |
| US20190218308A1 (en) | 2019-07-18 |
| CA3074588A1 (en) | 2019-04-11 |
| IL273414A (en) | 2020-05-31 |
| EP3692068A1 (en) | 2020-08-12 |
| AU2018346447A1 (en) | 2020-03-19 |
| CN111542539A (en) | 2020-08-14 |
| CN111542539B (en) | 2023-10-20 |
| KR20200060471A (en) | 2020-05-29 |
| WO2019068907A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273414A (en) | Restoration of t cell activity via the cd39/cd73 axis | |
| HK1254723A1 (en) | Active stylus ring electrode | |
| EP3601552A4 (en) | Polypeptides having dnase activity | |
| EP3349669A4 (en) | Vessel prosthesis | |
| EP3322383A4 (en) | Prosthetic heart valve | |
| IL268058A (en) | Compositions and methods for the depletion of cd137plus cells | |
| EP3429512A4 (en) | Flexible members for anchoring to the body | |
| SG11201610077TA (en) | Active panel demarcation | |
| EP3600350A4 (en) | Biological scaffold comprising therapeutic cells | |
| EP3515467C0 (en) | Ophthalmic compositions comprising ciclosporin | |
| EP3344156A4 (en) | Implantable nuclear prosthesis | |
| GB2551933B (en) | Paleogeographic reconstruction of an area of the earth crust | |
| EP3651638A4 (en) | Imaging to determine electrode geometry | |
| EP3624858A4 (en) | High activity regulatory elements | |
| EP3563809A4 (en) | Covered stent | |
| EP3243480A4 (en) | Dental implant bolt fastening structure | |
| EP3733120A4 (en) | Covered stent | |
| EP3677221A4 (en) | Covered stent | |
| IL261891A (en) | Active retina implant | |
| EP3656861A4 (en) | Active mmp9-binding peptide | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| EP3728562A4 (en) | Cardiac microtissue and uses thereof | |
| EP3094347A4 (en) | Methods for enhancing the delivery of active agents | |
| EP3648807A4 (en) | Compositions and methods for improving cardiac function | |
| EP3606772A4 (en) | Active force cancellation at structural interfaces |